QLS5132 combination therapy for advanced solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This trial tests a new drug called QLS5132, alone or in combination, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has spread or cannot be removed with surgery.
- Your cancer can be measured on scans like CT or MRI.
- You are able to perform most daily activities (with some help if needed).
- Your organs (liver, kidneys, bone marrow) are working well enough based on blood tests.
- You have recovered from side effects of prior cancer treatments (except hair loss, or mild numbness/tingling in hands or feet).
- You have not taken certain drugs that target CLDN6 or contain topoisomerase I inhibitors (like some chemotherapy or antibody-drug conjugates).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This Phase 1 trial tests the safety and how the medicine works in the body, and also looks at early signs of effectiveness. It is for adults with advanced solid tumors, and for Phase 1b specifically, the tumor must show a marker called GPC3.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.